Oncology CRO Email us info@sms-oncology.com
Follow us on

The 4D oncology CRO

Drug – Data – Dossier

The path to successful development of oncology drugs is geared by generation of clinical data that builds up a compliant regulatory dossier. Oncology drug development is complex and direction is required to navigate a safe passageway by avoiding risks and leveraging opportunities to increase the chances of success.


SMS-oncology adds an extra dimension to clinical cancer research by providing direction to our sponsors. During the study we turn complex data into meaningful insights using our oncology expertise. This information helps our sponsors to make informed decisions, stay in control, mitigate risks, identify opportunities and collect the right data to build the regulatory dossier. SMS-oncology: an oncology CRO adding value by providing direction.

Our oncology services

Clinical operations Read more

Clinical operations

From initiation and implementation to completion of oncology clinical trials with a specialization in:
• Early phase oncology trials
• Immuno-oncology trials

Consultancy Read more


From strategic expert advice on oncology drug development and trial design to protocol writing and scientific advisory boards.

4D service Read more

4D service

From upfront strategic advice translated into clinical operations to frequent meaningful insights during study conduct.

Our advantages

Responsiveness, Quality & Flexibility
  • Responsive and "right-sized" project teams for close collaboration, flexibility and fast-decision making
  • Close and personal involvement of the management team ensuring a high standard of quality
  • Delivering tailor made solutions by offering full or functional services as needed
Oncology Experts
  • In-depth knowledge of the complex nature of early phase oncology and immuno-oncology studies
  • Dedicated professionals with oncology know-how and experience in all functions of the company
  • Extensive network of Key Opinion Leaders throughout Europe
  • Proactively addressing challenges before they turn into hurdles
  • Strategic clinical development advice that can be directly translated into clinical operations
  • Turning complex data into meaningful insights during study conduct using our oncology expertise


24 May 2016

Two very interesting blogs CIMT 2016 "Mechanisms of efficacy in cancer immunotherapy" by Jasmijn Hubers (Medical Monitor) and CIMT 2016 - Rise of mRNA therapeutics, a relatively new class of treatment by Julia Holland (Consultant) are now online!

10-12 May 2016

Our colleagues Raymond Hoffmans, Julia Holland, Jasmijn Hubers and Lindy Bosch are attending the largest European meeting on cancer immunotherapy, the CIMT Annual Meeting, in Mainz!

19 May 2016

Our colleagues Raymond Hoffmans (CBDO) and Lindy Bosch (BD) are attending the Anglonordic Life Science Conference XIII in London, UK!

Conference schedule

26 May 2016

Knowledge for Growth, Ghent, Belgium

14-15 September 2016

Nordic Life Science (NLS) Days, Stockholm, Sweden

7-9 November 2016

BIO-Europe, Cologne, Germany

Recent blog posts